[go: up one dir, main page]

AR054183A1 - Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. - Google Patents

Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.

Info

Publication number
AR054183A1
AR054183A1 ARP050105492A ARP050105492A AR054183A1 AR 054183 A1 AR054183 A1 AR 054183A1 AR P050105492 A ARP050105492 A AR P050105492A AR P050105492 A ARP050105492 A AR P050105492A AR 054183 A1 AR054183 A1 AR 054183A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
carbamoyl
sulfamoyl
optionally substituted
Prior art date
Application number
ARP050105492A
Other languages
English (en)
Inventor
L Almeida
B Aquila
D Cook
S Cowen
L Dakin
J Ezhuthachan
S Ioannidis
J Lee
S Lee
P Lyne
T Pontz
D Scott
M Su
X Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR054183A1 publication Critical patent/AR054183A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Procesos para la preparacion de dichos compuestos químicos, composiciones farmacéuticas que los contienen y su uso en la fabricacion de medicamentos de utilidad en la produccion de un efecto anti-cáncer en un animal de sangre caliente como por ejemplo el hombre. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1): donde: el anillo A es fenilo un anillo heterocíclico monocíclico de 5 o 6 miembros totalmente-insaturado; donde dicho fenilo o anillo heterocíclico puede estar fusionado a un carbociclilo o heterociclilo de cinco o seis miembros formando un anillo bicíclico; y donde si dicho anillo heterociclilo o anillo heterocíclico contiene una porcion -NH- ese nitrogeno puede estar opcionalmente substituido por un grupo seleccionado entre R5; R1 es un substituyente sobre carbono y se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N, N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, alquil C1-6S(O)a donde a es entre 0 y 2, alcoxicarbonilo C1-6, alcoxicarbonilamino C1-6, N- (alquil C1-6)sulfamoilo, N,N-(alquiI C1-6)2sulfamoilo, N-(alquil C1-6)-N-(alcoxi C1-6)sulfamoil , N,N'-(alquiI C1-6)2 ureído, N'N'-(alquil C1-6)2ureído, N-(alquil C1-6)-N'N-(alquil C1-6)2ureído, alquilsulfonilamino C1-6, carbociclil-R6- o heterociclil-R7-; donde R1 puede estar opcionalmente substituido sobre carbono con uno o más R8; y donde si dicho heterociclilo contiene una porcion -NH- ese nitrogeno puede estar opcionalmente substituido con un grupo seleccionado entre R9; n se selecciona entre 0-4; donde los valores de R1 pueden ser iguales o diferentes; R2 se selecciona entre hidrogeno, halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, alquil C1-6 S(O)d donde a es entre 0 y 2, alcoxicarbonilo C1-6, N- (alquil C1-6)sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, alquilsulfonilamino C1-6, carbociclil-R10- o heterociclil-R11-; donde R2 puede estar opcionalmente substituido sobre carbono con uno o más R12; y donde si dicho heterociclilo contiene una porcion -NH-, ese nitrogeno puede estar opcionalmente substituido con un grupo seleccionado entre R13; R3 se selecciona entre halo, hidroxi, ciano, metilo, metoxi or hidroximetilo; R4 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, ureido, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N- (alquil C1-6)2carbamoilo, alquil C1-6 S(O)a donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(alquil C1-6)sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, alquilsulfonilamino C1-6, carbociclil-R14- o heterociclil-R15-; donde R4 puede estar opcionalmente substituido sobre carbono con uno o más R16; y donde si dicho heterociclilo contiene una porcion -NH- ese nitrogeno puede estar opcionalmente substituido con un grupo seleccionado entre R17; m se selecciona entre 0-4; donde los valores de R4 pueden ser iguales o diferentes; R8 y R12 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6,alcoxi C1-6, alcanoiloxi C1- 6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, N-(alquiI C1-6)-N-(alcoxi C1-6)amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, alquil C1-6 S(O)a donde a es entre 0 a 2, alcoxicarbonilo C1-6, N-(alquil C1- 6)sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, alquilsulfonilamino C1-6, carbociclil-R18- o heterociclil-R19-; donde R8 y R12 pueden estar en forma independiente entre sí opcionalmente substituido sobre carbono con uno o más R20; y donde si dicho heterociclilo contiene una porcion -NH- ese nitrogeno puede estar opcionalmente substituido con un grupo seleccionado entre R21; R16 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, alquil C1-6 S(O)a donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(alquil C1-6)sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, alquilsulfonilamino C1-6, carbociclil-R22- o heterociclil-R23-; donde R16 puede estar opcionalmente substituido sobre carbono con uno o más R24; y donde si dicho heterociclilo contiene una porcion -NH- ese nitrogeno puede estar opcionalmente substituido con un grupo seleccionado entre R25; R6, R7, R10, R11, R14, R15, R18, R19, R22 y R23 se seleccionan independientemente entre un enlace directo, -O-, - N(R26)-, -C(O)-, -N(R27)C(O)-, -C(O)N(R28)-, -S(O)s-, -SO2N(R29)- o -N(R30)SO2-; donde R26, R27, R28, R29 y R30 se seleccionan independientemente entre hidrogeno o alquilo C1-6 y s es 0-2; R5, R9, R13, R17, R21 y R25 se seleccionan en forma independiente entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R20 y R24 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N- etilamino, acetilamino, N-metilcarbamoilo, N-etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, fenilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N- metilsulfamoilo, N-etilsulfamoilo, N,N-dimetilsulfamoilo, N,N-dietilsulfamoilo o N-metil-N-etilsulfamoilo; o una sal aceptable para uso farmacéutico del mismo; con la condicion de que el compuesto no sea: N-[4-cloro-3-({[6-(4-metilpiperazin-1- yl)piridin-3-il]amino}carbonil)fenil]-2-morfolin-4-ilisonicotinamida; N-[4-cloro-3-({(6-(4-etilpiperazin-1-il)piridin-3-il]amino}carbonil)fenil]-2-morfolin-4-ilisonicotinamida; N-{4-cloro-3-[({6-[[3-(dimetilamino)propil](metil)amino]piridin-3-il} amino)carbonil]fenil}-2-morfolin-4-ilisonicotinamida; N-{4-cloro-3-[({6-[[2-(dimetilamino)etil](metil)amino]piridin-3-il}amino)carbonil] fenil}-2-morfolin-4-ilisonicotinamida; o N-[4-cloro-3-({[6-(4-metil-1,4-diazepan-1-il)piridin-3- il]amino}carbonil)fenil]-2-morfolin-4-ilisonicotinamida.
ARP050105492A 2004-12-22 2005-12-22 Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. AR054183A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63923404P 2004-12-22 2004-12-22

Publications (1)

Publication Number Publication Date
AR054183A1 true AR054183A1 (es) 2007-06-06

Family

ID=35953912

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105492A AR054183A1 (es) 2004-12-22 2005-12-22 Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.

Country Status (17)

Country Link
EP (1) EP1831198B1 (es)
JP (1) JP2008525406A (es)
KR (1) KR20070091675A (es)
CN (1) CN101128454A (es)
AR (1) AR054183A1 (es)
AT (1) ATE427946T1 (es)
AU (1) AU2005317870A1 (es)
BR (1) BRPI0519181A2 (es)
CA (1) CA2589773A1 (es)
DE (1) DE602005013819D1 (es)
IL (1) IL183527A0 (es)
MX (1) MX2007007574A (es)
NO (1) NO20072784L (es)
TW (1) TW200634003A (es)
UY (1) UY29300A1 (es)
WO (1) WO2006067446A1 (es)
ZA (1) ZA200705117B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006137376A1 (ja) 2005-06-21 2006-12-28 Mitsui Chemicals, Inc. アミド誘導体ならびに該化合物を含有する殺虫剤
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8648116B2 (en) * 2005-07-21 2014-02-11 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903105A1 (fr) 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
CN101616667A (zh) * 2006-10-27 2009-12-30 百时美施贵宝公司 可用作激酶抑制剂的杂环酰胺化合物
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8461189B2 (en) 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
FR2925900B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2009111279A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
JP2011513332A (ja) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
MX2010009410A (es) 2008-02-29 2010-11-30 Array Biopharma Inc Compuestos del inhibidor de raf y métodos de uso de los mismos.
KR100970670B1 (ko) 2008-04-22 2010-07-15 계명대학교 산학협력단 세포증식 억제제로서 유용한 벤즈아미드 유도체 및 그제조방법
EP2184273A1 (de) * 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
EP2253617A1 (de) 2009-05-20 2010-11-24 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
RU2012109233A (ru) * 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CN102140093A (zh) * 2010-02-03 2011-08-03 上海源力生物技术有限公司 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
KR101699822B1 (ko) * 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
ES2720066T3 (es) * 2013-12-09 2019-07-17 Unichem Lab Ltd Mejora del proceso de preparación de (3R,4R)-(1-bencil-4-metilpiperidín-3-il)-metilamina
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361800B2 (en) * 2013-12-13 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
RU2729194C2 (ru) 2013-12-27 2020-08-05 Займворкс Инк. Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
EP3193603A4 (en) * 2014-09-10 2018-02-28 Epizyme, Inc. Isoxazole carboxamide compounds
RU2723651C2 (ru) 2014-09-17 2020-06-17 Займворкс Инк. Цитотоксические и антимитотические соединения и способы их применения
EP3209648B1 (en) 2014-10-22 2020-03-11 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PT3319959T (pt) 2015-07-06 2021-12-06 Alkermes Inc Inibidores hetero-halo de histona desacetilase
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
HUE055197T2 (hu) 2016-03-09 2021-11-29 Raze Therapeutics Inc 3-Foszfoglicerát-dehidrogenáz inhibitorok és alkalmazásuk
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
CN106187911A (zh) * 2016-07-04 2016-12-07 烟台凯博医药科技有限公司 2‑三氟甲基嘧啶‑4‑羧酸及其衍生物和制备方法
CN106632021A (zh) * 2016-09-27 2017-05-10 中国药科大学 2‑取代异烟酸类化合物、其制备方法及其用途
JP6755775B2 (ja) * 2016-11-04 2020-09-16 富士アミドケミカル株式会社 ４−フルオロイソキノリンの製法
CA3049443A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
BR112020018601A2 (pt) 2018-03-14 2020-12-29 Janssen Sciences Ireland Unlimited Company Regime de dosagem de modulador de montagem de capsídeo
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025096979A1 (en) 2023-11-02 2025-05-08 Arcus Biosciences, Inc. Thiazole compounds as kit inhibitors and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761291B2 (en) * 1999-03-17 2003-05-29 Astrazeneca Ab Amide derivatives
DK1499311T3 (da) * 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer

Also Published As

Publication number Publication date
ATE427946T1 (de) 2009-04-15
AU2005317870A1 (en) 2006-06-29
BRPI0519181A2 (pt) 2008-12-30
WO2006067446A1 (en) 2006-06-29
CA2589773A1 (en) 2006-06-29
IL183527A0 (en) 2007-09-20
ZA200705117B (en) 2008-10-29
EP1831198A1 (en) 2007-09-12
JP2008525406A (ja) 2008-07-17
EP1831198B1 (en) 2009-04-08
CN101128454A (zh) 2008-02-20
TW200634003A (en) 2006-10-01
UY29300A1 (es) 2006-07-31
NO20072784L (no) 2007-07-17
KR20070091675A (ko) 2007-09-11
MX2007007574A (es) 2007-07-24
DE602005013819D1 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
AR054183A1 (es) Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.
AR053992A1 (es) Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
AR055249A1 (es) Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas
AR049662A1 (es) Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer
AR064208A1 (es) Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas.
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
AR062406A1 (es) Derivados de quinazolina como inhibidores de b-raf
AR053683A1 (es) Derivados de piperidina con actividad antibacteriana
AR070493A1 (es) Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas.
AR056354A1 (es) DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR056210A1 (es) 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa
AR061653A1 (es) Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3)
AR052170A1 (es) Derivados de pirimidina utiles por su actividad anti-proliferacion celular
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
AR047702A1 (es) Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular
AR064130A1 (es) Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas.
AR050545A1 (es) Derivados de quinazolinonas y su uso como inhibidores de b-raf
AR040408A1 (es) Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR046615A1 (es) Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos
AR056184A1 (es) Compuestos derivados de pirazol, composicion farmaceutica en base a aquellos y su uso para la fabricacion de medicamentos
AR033836A1 (es) Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion
AR041594A1 (es) Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1
AR072045A1 (es) Derivados heterociclicos de urea y metodos para utilizarlos
AR072047A1 (es) Compuestos heterociclicos utiles para inhibir la adn girasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal